Central Nervous System Therapeutics Market Report 2025

The central nervous system therapeutics market size has grown strongly in recent years. It will grow from $123.53 billion in 2024 to $134.99 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the rising prevalence of neurological disorders, increasing awareness of mental health issues, expansion of research and development activities, growing demand for personalized medicine, and the facilitation of trade agreements supporting the CNS therapeutics market.

The central nervous system therapeutics market size is expected to see strong growth in the next few years. It will grow to $190.07 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to the rising prevalence of central nervous system (CNS) disorders, increased focus on developing novel therapeutics, growing incidence of conditions such as Alzheimer’s disease, an expanding aging population, and higher demand for effective treatments. Major trends during this period include the use of artificial intelligence in diagnostics, advancements in antidepressant drug development, innovations in drug delivery systems, progress in neurology research, and identification of novel biomarkers.

The increasing prevalence of mental health disorders is expected to propel the growth of the central nervous system (CNS) therapeutics market going forward. Mental health disorders encompass a range of conditions affecting thinking, feeling, behavior, or mood, including depression, anxiety disorders, schizophrenia, and bipolar disorder. Rising exposure to chronic stress contributes to these disorders by disrupting emotional regulation, weakening coping mechanisms, and increasing susceptibility to anxiety, depression, and burnout. CNS therapeutics address these disorders by targeting brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, in December 2025, the Bristol City Council, a UK-based local government authority, reported that 66,815 patients aged 18 and over were recorded on GP practice depression registers in Bristol in 2022/23, representing a 6% increase from 2021/22. Therefore, the increasing prevalence of mental health disorders is driving the growth of the central nervous system (CNS) therapeutics market.

Key companies in the central nervous system (CNS) therapeutics market are focusing on innovative approaches such as capsid engineering to enhance targeted gene delivery, therapeutic efficacy, and blood-brain barrier penetration in neurological disorders. Capsid engineering involves optimizing the protein shell of viral vectors, typically adeno-associated viruses (AAVs), for gene therapy. For example, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF 01, a novel AAV for CNS delivery using its ALIGATER platform. The vector demonstrated 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus compared to AAV9 at the same dose, with equivalent expression achieved at one-fifth of the dose. It also reduced off-target expression in peripheral organs while maintaining a favorable safety profile, highlighting its potential to improve CNS gene therapy outcomes with precision and lower systemic risk.

In June 2025, Supernus Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Sage Therapeutics Inc. for an undisclosed amount to expand its neuroscience portfolio, strengthen its position in the CNS market, and accelerate the development of innovative treatments for depression and other mood disorders. Sage Therapeutics Inc. is a US-based biopharmaceutical company specializing in CNS therapeutics.

Major players in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Kyverna Therapeutics Inc., Immunic Inc., LEXEO Therapeutics Inc., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., and Assertio Holdings Inc.

North America was the largest region in the central nervous system therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in central nervous system therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the central nervous system therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Central nervous system (CNS) therapeutics refers to drugs and treatments developed to manage and treat disorders of the brain and spinal cord. These therapies target conditions such as depression, epilepsy, Parkinson’s disease, and multiple sclerosis, aiming to restore neurological function, alleviate symptoms, and enhance patients’ quality of life. CNS therapeutics may include pharmaceuticals, biologics, and advanced neurotechnological interventions.

The primary drug classes in CNS therapeutics include anesthetics, anticonvulsants, antiemetics, CNS stimulants, pain relievers, and others. Anesthetics are medications that block pain or induce unconsciousness during medical procedures. These drugs address a variety of diseases, including neurovascular disorders, mental health conditions, degenerative and genetic disorders, substance abuse, autoimmune and inflammatory diseases, CNS trauma, infectious diseases, and CNS cancers. They are distributed through channels such as hospital and retail pharmacies and are applied across hospitals, clinics, homecare, and other healthcare settings.

The central nervous system therapeutics market research report is one of a series of new reports that provides central nervous system therapeutics market statistics, including central nervous system therapeutics industry global market size, regional shares, competitors with a central nervous system therapeutics market share, central nervous system therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system therapeutics industry. This central nervous system therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The central nervous system therapeutics market consists of sales of sodium channel blockers, amphetamines, and neuroprotective agents. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.